AMAG Pharmaceuticals — Q2 2017 Earnings Presentation
40 slides from AMAG Pharmaceuticals's earnings presentation, Aug 3, 2017
Slide 1: AMAG Pharmaceuticals Q2-2017 Financial Results & Corporate Update
AMAG Pharmaceuticals Q2-2017 Financial Results & Corporate Update August 3, 2017 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expe
Slide 3: Q2-2017 Earnings Call Agenda
Q2-2017 Earnings Call Agenda Q2-2017 Highlights and Recent Events 1 5 Q&A 2 Product Portfolio Commercial Overview 4 2017 Key Priorities and Closing Remarks 3 Financial Update and Guidance 3
Slide 4: Q2-2017 Highlights and Recent Events
Bill Heiden President & CEO Q2-2017 Highlights and Recent Events 4
Slide 5: Q2-2017 Financial Highlights
Q2-2017 Financial Highlights $127.4 $158.4 Q2-2016 Q2-2017 24% increase driven by strong growth across product portfolio GAAP Total Net Revenues ($M) Makena revenue CBR revenue Feraheme/MuGard revenue 5
Slide 6: Q2-2017 Financial Highlights
Q2-2017 Financial Highlights $18.1 $3.6 Q2-2016 Q2-2017 Investing in new product launch and development while maintaining strong cash flows Ended Q2-2017 with ~$400M in cash and investments $50.1 Q2-2016 Q2-2017 GAAP Operating Income ($M) Non-GAAP Adj. EBITDA1 ($M) 1 See slide 37 for reconciliation
Slide 7: Strong Execution in Q2-2017
Strong Execution in Q2-2017 Highlights and Recent Events Closed Endoceutics licensing transaction, hired and trained new sales team, and launched Intrarosa Drove record quarterly Makena sales to over $102M and received FDA acceptance for review of Makena subcutaneous (sub-q) auto-injector sNDA
Slide 8: AMAG's Expanding Portfolio of Products
AMAG’s Expanding Portfolio of Products Feraheme Treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) The only FDA-approved therapy to reduce recurrent preterm birth in certain at-risk women World’s largest umbilical cord stem cell collection and storage
Slide 9: Product Portfolio Commercial Overview
Product Portfolio Commercial Overview Nik Grund Chief Commercial Officer 9
Slide 10: Women's Health: Intrarosa Launched July 24, 2017
Launched July 24, 2017 W O M E N ’ S H E A L T H : I N T R A R O S A 10
Slide 11: Dyspareunia: Sizable Untapped Treatment Market
Affected, but not currently seeking treatment Utilizing OTC treatments Dyspareunia: Sizable Untapped Treatment Market Currently on Rx estrogen therapy Local (intra-vaginal) estrogen therapies = sales of >$1B per year1 1.7M women2 ~6M women2 ~12M women2 W O M E N ’ S H E A L T H : I N T R A R O S A ~
Slide 12: Well-Planned Phased Approach for Commercial Launch
Full HCP Campaign NAMS October 2017 Phase 3 Well-Planned Phased Approach for Commercial Launch Coming Soon ACOG May 2017 Phase 1 Now Available Launch Day 1 July 2017 Phase 2 Patient Engagement Programs 1H-2018 Phase 4 Time Sales W O M E N ’ S H E A L T H : I N T R A R O S A 12
Slide 13: Launch Day 1 – Now Available
Inventory broadly available in wholesaler distribution network Product available at more than 5,000 retail pharmacies Samples being distributed to HCP offices to facilitate new patient starts Commercial insurance coverage and copay savings program in place Launch Day 1 – Now Available W O M
Slide 14: Commercial Lives Covered for Intrarosa
Commercial Lives Covered for Intrarosa Approximately 2/3 of prescriptions for VVA are commercial pay1 – Top 18 accounts represent >85% of covered lives2 Unrestricted coverage 14% and growing W O M E N ’ S H E A L T H : I N T R A R O S A 1 IMS FIA data, last 24 months, July 2017. 2 Market researc
Slide 15: Commercial Copay Savings Program in Place
Commercial Copay Savings Program in Place Remove Cost as a Barrier in Order to Maximize Launch Uptake W O M E N ’ S H E A L T H : I N T R A R O S A Comprehensive commercial copay savings program – $0 copay first month on therapy (regardless of formulary access) – Refill copays are no greater than
Slide 16: AMAG Well Positioned for a Successful Launch
62% 14% 24% Not covered Covered (unrestricted) Covered (PA/ST) AMAG Well Positioned for a Successful Launch Launch Priorities to Watch M A T E R N A L H E A L T H : I N T R A R O S A Commercial Lives Covered1 Create affordable access for patients ‒ Increase percentage of covered lives 1 Increase phy
Slide 17: In Summary
Differentiated mechanism of action Only FDA-approved non-estrogen local product1 for moderate- to-severe dyspareunia due to menopause – Only product without a boxed warning Well-planned launch strategy to quickly capture market share Significant market opportunity with sizeable revenue poten
Slide 18: Proven Commercial Execution Capabilities
Proven Commercial Execution Capabilities $78.4 $86.5 $102.7 Q2-2016 actual 1Q-2017 actual 2Q-2017 actual 3Q-2017 est. 4Q-2017 est. Record Net Makena Sales ($M) 31% M A T E R N A L H E A L T H : M A K E N A On track to achieve 2017 Makena revenue guidance of $410M - $440M 18
Slide 19: Makena: Continued Growth
Makena: Continued Growth 2017 Makena Growth Drivers M A T E R N A L H E A L T H : M A K E N A 1 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market research data conducted by AMAG. 2 AMAG estimates market opportunity based o
Slide 20: CBR: Attractive Recurring Revenue Stream
$24.4 $28.0 Q2-2016 Q2-2017 $29.4 $29.4 Q2-2016 Q2-2017 GAAP CBR Revenue ($M) Non-GAAP CBR Revenue1 ($M) CBR: Attractive Recurring Revenue Stream M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y 1 Non-GAAP CBR revenue includes purchase accounting adjustments related to CBR deferred re
Slide 21: CBR 2017 Growth Drivers
CBR 2017 Growth Drivers Differentiate CBR’s offerings – Increase/stabilize first time enrollments 1 Build value proposition on storing newborn stem cells – Harmonizing annual storage price – Stabilized new enrollment pricing 2 Leverage advancements in stem cell research with OB/GYN’s and pregnant fa
Slide 22: Solid Financial Performance; Expected Future Growth
Solid Financial Performance; Expected Future Growth $24.3 $27.5 Q2-2016 Q2-2017 Feraheme Revenue1 ($M) 13% H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 2017 Growth Drivers Continued growth in key segments Pull through recent GPO access wins Optimize net revenue per gram Prepare f
Slide 23: Large IV Iron Market Opportunity of $780M
Large IV Iron Market Opportunity of $780M1,2 Feraheme 25%3 Other IV irons 75%3 Current Addressable Market: $390M3 Additional Addressable Market: $390M ‒ Iron deficiency anemia caused by other diseases – Iron deficiency anemia caused by chronic kidney disease Label expansion doubles our addressable m
Slide 24: IV Iron Market Represents Small Subset of Patients Who Suffer from IDA
IV Iron Market Represents Small Subset of Patients Who Suffer from IDA Opportunity to convert from oral to IV treatments IDA-CKD Patients Majority under the care of current AMAG call points; hematology / oncology & hospital infusion centers Diagnosed IDA Patients Under the care of other physicia
Slide 25: Financial Update and Guidance
Financial Update and Guidance Ted Myles Chief Financial Officer 25
Slide 26: Continued Revenue Growth and Portfolio Investments
$236.4 $297.8 $25.5 $(36.4) 1 1 $127.4 $158.4 $3.6 $18.1 Q2-2016 Q2-2017 Makena revenue CBR revenue Feraheme/MuGard revenue GAAP Operating income (loss) 24% 1H-2016 1H-2017 26% GAAP Financials for the 3-months Ended June 30 ($M) GAAP Financials for the 6-months Ended June 30 ($M) 1 Excludes $273,0
Slide 27: Continued Revenue Growth and Portfolio Investments
Continued Revenue Growth and Portfolio Investments $250.3 $112.1 $300.6 $107.7 1H-2016 1H-2017 20% Makena revenue CBR revenue Feraheme/MuGard revenue Non-GAAP adjusted EBITDA $132.5 $64.6 $159.8 $50.1 Q2-2016 Q2-2017 21% 1 See slide 37 for a reconciliation of GAAP to non-GAAP financial results. No
Slide 28: Affirming 2017 Financial Guidance
Affirming 2017 Financial Guidance ($M) 2017 GAAP Guidance 2017 Non-GAAP Guidance1 Makena sales $410 - $440 $410 - $440 Feraheme/MuGard sales $100 - $110 $100 - $110 CBR revenue $110 - $120 $115 - $1252 Intrarosa $5 - $15 $5 - $15 Total revenue $625 - $685 $630 - $690 Net income (loss) ($62) - ($31)1
Slide 29: Revised Liability Profile: Before – Early Maturing Debt Profile
Revised Liability Profile to Align with Business Strategy BEFORE – Early Maturing Debt Profile Key Items Before Cash: $558M1 Outstanding debt balance: $1,024M1 Interest rate:2 5.9% Total annual interest cost:2 $60M 2017 adj. EBITDA guidance:3 $235M Leverage:4 4.4x Capital Structure $18 $18 $218 $18
Slide 30: Revised Liability Profile: After – Extended Debt Maturity Profile
Revised Liability Profile to Align with Business Strategy AFTER – Extended Debt Maturity Profile Key Items Before After Cash: $558M $399M1 Outstanding debt balance: $1,024M $861M1 Interest rate:2 5.9% 5.9% Total annual interest cost:2 $60M $50.8M 2017 adj. EBITDA guidance:3 $235M $235M Leverage:4 4.
Slide 31: Financial Results and Revamped Balance Sheet Support Evolving Business Model
Debt maturities now align with business strategy Strong cash balance of $400M and positive EBITDA generation supportive of investments in: – Next generation products in current portfolio – Advancement of new product portfolio (Intrarosa and bremelanotide) – Expansion of portfolio through busines
Slide 32: 2017 Key Priorities & Closing Remarks
2017 Key Priorities & Closing Remarks Bill Heiden President & CEO 32
Slide 33: AMAG Portfolio: Multiple Value Drivers
AMAG Portfolio: Multiple Value Drivers Milestone 2017 2018 INTRAROSA Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Commercial launch in dyspareunia Initiate Phase 3 female sexual dysfunction study MAKENA AUTO-INJECTOR PROGRAM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Topline PK data sNDA submission Expected FDA action and commercial launc
Slide 34: 2H-2017 Key Priorities
2H-2017 Key Priorities Intrarosa Drive successful launch ‒ Continue to increase the number of covered lives ‒ Market share ‒ NRx and TRx (growth) Makena Increase patient market share and adherence to therapy Prepare for launch of sub-q auto-injector in Q1-20181 Prepare for potential competit
Slide 35: Q&A
amag AMAG Pharmaceuticals Q&A
Slide 36: Appendix
Appendix 36
Slide 37: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) GAAP operating income (loss) Purchase accounting adjustments related to CBR deferred revenue Depreciation and intangible asset amortization Non-cash inventory step-up adjustments Stock-based compensation Adjustments to contingent consideratio
Slide 38: Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance 2017 Financial Guidance ($M) GAAP net loss ($62) – ($31) Adjustments: Interest expense, net 66 Loss on debt extinguishment 10 Provision for income tax benefit (37) – (18) Operating income (loss) ($23) – $27 Purchase accounting adjustments re
Slide 39: Share Count Reconciliation
Share Count Reconciliation 1 Employee equity incentive awards, convertible notes and warrants would be anti-dilutive in this period. 2 Reflects the Non-GAAP dilutive impact of employee equity incentive awards. (M) Q2-2017 Q2-2016 YTD 2017 YTD 2016 Weighted average basic shares outstanding 35.1 34.2
Slide 40: AMAG Pharmaceuticals Q2-2017 Financial Results & Corporate Update
AMAG Pharmaceuticals Q2-2017 Financial Results & Corporate Update August 3, 2017 40